SCHEMBL10126528

SCHEMBL10126528

CSc1nc(Cl)c(C(N)=O)c(Nc2ccc(S(=O)(=O)N3CCCCC3)c(C)c2)n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
THRB P10828 1/20 0.43
CNR2 P34972 1/20 0.41
MITF O75030 2/20 0.41
ALDH1A1 P00352 1/20 0.41
HTT P42858 1/20 0.41
EPHX2 P34913 3/20 0.41
ATAD2 Q6PL18 2/20 0.40
CECR2 Q9BXF3 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
RAB9A P51151 2/20 0.39
LMNA P02545 2/20 0.39
CNR1 P21554 1/20 0.39
TP53 P04637 1/20 0.39
PRMT5 O14744 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10157042 0.90 MCOLN3 (0.44) MAPTTHRBALDH1A1SMN1; SMN2RAB9A
SCHEMBL10126533 0.85 CA1 (0.44) MAPTALDH1A1CA1CA2CA7
SCHEMBL10126522 0.83 MAPT (0.42) MAPTTHRBMITFALDH1A1HTT
SCHEMBL328277 0.82 CNR2 (0.43) CNR2JAK2JAK1LMNACNR1
SCHEMBL10126471 0.82 HTT (0.49) MAPTMITFALDH1A1HTTLMNA
SCHEMBL328295 0.81 CA1 (0.44) MAPTCA1CA2CA7
SCHEMBL10126731 0.80 MAPT (0.47) MAPTTHRBCNR2MITFALDH1A1
SCHEMBL10126505 0.80 PTK6 (0.45) CNR2CNR1
SCHEMBL10126599 0.80 CNR2 (0.43) MAPTCNR2ALDH1A1HTTSMN1; SMN2
SCHEMBL10126577 0.79 MAPT (0.44) MAPTMITFALDH1A1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487491-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2016-11-08 US disclosed
US-8969336-B2 Diamino heterocyclic carboxamide compound ASTELLAS PHARMA INC. (JP) 2015-03-03 US disclosed
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND ASTELLAS PHARMA INC. (JP) 2014-12-18 US disclosed
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND WATERS TECHNOLOGIES CORPORATION (US) 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140371196-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 MAPT 3116/4885THRB 4052/4885CNR2 1453/4885
US-20120040968-A1 DIAMINO HETEROCYCLIC CARBOXAMIDE COMPOUND EML4, ALK, ERBB4 MAPT 3116/4885THRB 4052/4885CNR2 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.